LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Home・Akcijų sąrašas・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Uždarymo kaina

15.97 1.27

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

15.45

Max

16.01

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-1.4M -14M
Pelnas, tenkantis vienai akcijai	-0.15
Darbuotojai	37
EBITDA	-2.7M -15M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+99.87% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-18M 1.3B
Ankstesnė atidarymo kaina	14.7
Ankstesnė uždarymo kaina	15.97

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

3.165 / 3.5827 Palaikymas ir pasipriešinimas

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-12 22:50; UTC

Uždarbis

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

2026-05-12 22:49; UTC

Uždarbis

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

2026-05-12 22:32; UTC

Uždarbis

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

2026-05-12 23:48; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

2026-05-12 22:57; UTC

Rinkos pokalbiai

Uždarbis

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

2026-05-12 22:26; UTC

Uždarbis

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

2026-05-12 22:25; UTC

Uždarbis

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

2026-05-12 22:25; UTC

Uždarbis

Aristocrat Leisure Interim Dividend A$0.50/Security

2026-05-12 22:24; UTC

Uždarbis

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

2026-05-12 22:23; UTC

Uždarbis

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

2026-05-12 22:23; UTC

Uždarbis

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

2026-05-12 22:19; UTC

Uždarbis

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

2026-05-12 22:14; UTC

Uždarbis

CBA: Business Lending Continued to Grow Above System>CBA.AU

2026-05-12 22:14; UTC

Uždarbis

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

2026-05-12 22:13; UTC

Uždarbis

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

2026-05-12 22:12; UTC

Uždarbis

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

2026-05-12 22:12; UTC

Uždarbis

CBA 3Q New Home Loan Funding A$45B>CBA.AU

2026-05-12 22:11; UTC

Uždarbis

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

2026-05-12 22:11; UTC

Uždarbis

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

2026-05-12 22:10; UTC

Uždarbis

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

2026-05-12 22:09; UTC

Uždarbis

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

2026-05-12 22:09; UTC

Uždarbis

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

2026-05-12 22:08; UTC

Uždarbis

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

2026-05-12 22:07; UTC

Uždarbis

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

2026-05-12 22:06; UTC

Uždarbis

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

2026-05-12 22:06; UTC

Uždarbis

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

2026-05-12 22:05; UTC

Uždarbis

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

2026-05-12 22:04; UTC

Uždarbis

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

2026-05-12 22:04; UTC

Uždarbis

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

2026-05-12 22:04; UTC

Uždarbis

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

99.87% į viršų

12 mėnesių prognozė

Vidutinis 31.6 USD 99.87%

Aukščiausias 40 USD

Žemiausias 27 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Corvus Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

3.165 / 3.5827Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.